Report Description Table of Contents Pet Diabetes Care Devices Market: Introduction and Strategic Context The Global Pet Diabetes Care Devices Market was valued at USD 1.94 billion in 2025 and is projected to reach USD 3.24 billion by 2032, growing at a CAGR of 7.5%, according to Strategic Market Research. Veterinary diabetes devices support glucose and ketone monitoring and insulin delivery in companion animals. Key product groups are veterinary glucose meters, continuous glucose monitors, ketone-testing systems, insulin pens, and syringes. Connected applications enable data exchange between pet owners and veterinary teams. Insulin, oral therapies, prescription diets, consultations, and laboratory services act as demand drivers rather than device revenue streams. Market growth depends on durable equipment sales and recurring purchases of strips, sensors, needles, and syringes. The Addressable Animal Population Depends on Active Disease Management Diabetic dogs and cats represent the primary addressable population. Applying historical U.S. veterinary-clinic prevalence rates to approximately 89.7 million owned dogs and 73.8 million owned cats reported for 2024 produces an estimated pool of 211,692 diabetic dogs and 498,888 diabetic cats, or approximately 710,580 animals combined. These figures are analytical prevalence proxies rather than published national counts of diagnosed, treated, or device-using pets. By animal type, cats accounted for an estimated 58.0% market share and USD 1.13 billion in revenue in 2025. The feline segment is projected to reach approximately USD 1.94 billion by 2032, growing at a CAGR of 8.1%, supported by the larger estimated diabetic-cat population and expanding glucose and ketone-monitoring requirements. Dogs represented the remaining 42.0% share, equivalent to approximately USD 0.81 billion in 2025, and are projected to reach USD 1.30 billion by 2032 at a CAGR of 6.9%. International studies confirm that diabetes affects a small but commercially relevant share of companion animals. A UK primary-care study estimated canine diabetes prevalence at approximately 0.34%, while a later feline study reported a 0.39% one-year prevalence in 2019. Veterinary-attending populations may produce higher prevalence than the wider owned-pet population because animals visiting clinics are more likely to have existing health conditions. Using the supplied U.S. and European pet-population inputs produces an additional proxy of approximately 1.44 million diabetic dogs and cats across the United States and Europe. It should not be presented as a global patient count because it applies UK prevalence assumptions across several countries and combines inputs from different years. Pet ownership does not translate directly into device revenue. Addressable demand is constrained by diagnosis rates, survival, veterinary access, treatment initiation, monitoring intensity, adherence, and therapy choice. Feline remission and early death or euthanasia further reduce the pool of persistent annual device users. Recurring Consumables and Home Monitoring Shape Revenue Dynamics Blood-glucose meters and reusable insulin pens may remain in service for several years. Test strips, lancets, CGM sensors, pen needles, syringes, insulin cartridges, and ketone strips require repeated replacement and account for a larger share of lifetime spending per treated animal. Veterinary blood-glucose meters, test strips, and lancets formed the largest product group in 2025, accounting for an estimated 41.5% market share and USD 0.81 billion in revenue. The segment is projected to reach approximately USD 1.24 billion by 2032, expanding at a CAGR of 6.4%. Insulin-delivery devices, including pens, pen needles, cartridges, and syringes, represented approximately 29.5% of the market and USD 0.57 billion in 2025. This segment is expected to reach nearly USD 0.84 billion by 2032 at a CAGR of 5.7%. Continuous glucose monitoring systems accounted for an estimated 18.0% share, equivalent to USD 0.35 billion in 2025. CGMs are projected to expand at a faster CAGR of 11.1%, reaching approximately USD 0.73 billion by 2032. Ketone meters and testing strips represented approximately 7.0% and USD 0.14 billion in 2025 and are projected to reach USD 0.25 billion by 2032 at a CAGR of 9.3%. Connected monitoring applications and veterinary data platforms accounted for the remaining estimated 4.0% share, or approximately USD 0.08 billion, in 2025. Although still a smaller product category, the segment is projected to record the fastest CAGR of approximately 12.2%, reaching USD 0.17 billion by 2032 as suppliers integrate mobile applications and remote data exchange into meter and CGM portfolios. Current portfolios reflect this model. Zoetis sells AlphaTrak meters with proprietary strips, lancets, and control materials. PetTest combines meters with glucose and ketone strips, syringes, lancets, and digital services. WellionVet supplies glucose and ketone meters supported by separate strip and lancet lines. Merck Animal Health links its reusable VetPen to Vetsulin cartridges and single-use needles. Monitoring intensity changes over the treatment cycle. Newly diagnosed, unstable, or poorly controlled animals require more frequent checks than stable patients. Diabetic ketoacidosis creates concentrated demand for glucose and ketone testing in hospitals, while routine management increasingly shifts measurement into the home. The 2026 AAHA Diabetes Management Guidelines for Cats no longer recommend routine in-hospital blood-glucose curves for feline patients. At-home curves and CGMs can provide readings from the animal’s normal environment while reducing the effect of clinic-related stress. This change gives pet owners greater influence over product use and increases purchases of replacement strips, sensors, lancets, and related supplies between veterinary appointments. Pet owners and home-care users accounted for an estimated 58.0% end-user market share and approximately USD 1.13 billion in 2025. The segment is projected to reach approximately USD 1.94 billion by 2032, growing at a CAGR of 8.1%. Veterinary clinics and general veterinary hospitals represented approximately 34.0%, or USD 0.66 billion, and are forecast to reach USD 1.02 billion by 2032 at a CAGR of 6.4%. Specialty and emergency veterinary hospitals accounted for around 8.0% and USD 0.16 billion, with a projected CAGR of 8.4%, supported by intensive glucose and ketone monitoring in unstable and DKA cases. Connected systems support this transition. AlphaTrak 3, PetTest PetLink+, GluCurve, and other platforms allow owners to record or transfer glucose information for veterinary review. Suppliers are therefore competing across the complete owner-clinic workflow rather than through meter hardware alone. Home monitoring still faces practical barriers. Some owners struggle to obtain a sufficient blood sample, place or retain a sensor, manage repeated punctures, or continue testing over long periods. Animal resistance, product cost, owner confidence, and access to veterinary support influence whether an initial device purchase develops into recurring consumable demand. CGMs and Veterinary-Calibrated Meters Will Remain Complementary Human-market CGMs have created an additional competitive route into veterinary diabetes management. Abbott’s FreeStyle Libre sensors are used in dogs and cats despite not being calibrated specifically for veterinary patients. They provide multi-day glucose trends and may identify nocturnal hypoglycemia or fluctuations missed by a conventional clinic curve. By application, routine blood-glucose monitoring accounted for the largest estimated share of 45.0%, generating approximately USD 0.87 billion in 2025. The application is projected to reach around USD 1.37 billion by 2032, growing at a CAGR of 6.6%. Continuous glucose monitoring represented approximately 18.0% and USD 0.35 billion in 2025 but is forecast to expand at a faster CAGR of 11.1%, reaching approximately USD 0.73 billion by 2032. CGMs broaden device access because some sensors can be obtained through human pharmacies and medical-device channels. Human diabetes-device companies gain veterinary utilization without developing a dedicated animal-health portfolio, while veterinary suppliers compete through species-specific calibration, pet-focused application support, clinic distribution, and veterinary data portals. Continuous monitoring is unlikely to eliminate portable meters. Unexpected or low CGM readings may require confirmation with a veterinary-calibrated glucometer before treatment is changed. Sensors can also detach or fail before the intended wear period. Portable meters therefore remain relevant for spot checks, confirmation testing, home curves, and animals unsuitable for sensor placement. Species calibration remains an important differentiator. Glucose distribution differs among people, dogs, and cats, and human meters can produce inconsistent readings in animal patients. Zoetis AlphaTrak 3, PetTest, i-SENS VetMate, WellionVet, and Covetrus Vet GlucoGauge compete on veterinary calibration, small blood-sample requirements, strip availability, price, and data connectivity. Insulin Delivery Remains Stable as Oral Feline Drugs Change the Product Mix Dogs with established diabetes generally remain dependent on insulin, while many cats also require injectable therapy. This sustains demand for U-40 and U-100 syringes, reusable pens, cartridges, and pen needles. Insulin-administration applications accounted for an estimated 27.0% market share and approximately USD 0.52 billion in revenue in 2025. The segment is projected to reach around USD 0.78 billion by 2032, expanding at a CAGR of 5.9%. Merck Animal Health’s VetPen is designed for use with Vetsulin cartridges in dogs and cats. The portfolio includes 8 IU and 16 IU reusable pens, single-use needles, 2.7 mL cartridges, starter kits, dosing accessories, and digital tracking tools. Merck reports that close to 97% of owners in a three-week study considered VetPen easy to use. The company-reported result is not market-share evidence, but it indicates that owner convenience can influence long-term adherence and device choice. Syringes retain a substantial position because they are widely available, familiar to veterinarians, compatible with several insulin pathways, and generally less expensive at the initial purchase. Pens appeal to owners who value dial-based dosing, portability, and easier handling enough to accept proprietary cartridges and needles. The introduction of Bexacat and Senvelgo created a non-injectable option for carefully selected, newly diagnosed diabetic cats. FDA field studies indicated that both products were more than 80% effective in improving glycemic control among studied cats. These medicines can reduce demand for pens, cartridges, needles, and syringes in eligible animals, but they do not remove monitoring requirements. SGLT2-treated cats require careful surveillance because diabetic ketoacidosis or euglycemic diabetic ketoacidosis can develop without the high glucose readings normally associated with DKA. Blood or urinary ketone testing, glucose spot checks, body-weight monitoring, and assessment of clinical signs become more commercially relevant than injection products in this pathway. Ketone and diabetic-ketoacidosis monitoring applications accounted for an estimated 7.0% market share and approximately USD 0.14 billion in 2025. The segment is projected to grow at a CAGR of 9.3%, reaching approximately USD 0.25 billion by 2032. Treatment-response and feline-remission monitoring represented an additional estimated 3.0%, or USD 0.06 billion, and is projected to reach approximately USD 0.10 billion by 2032 at a CAGR of 8.7%. Routine CGM use may be less important for cats responding well to an oral SGLT2 medicine because the dose is not adjusted according to continuous readings. Ketone meters and strips gain greater strategic value. Cats that fail oral treatment, develop ketosis, or become insulin-dependent may move to injectable therapy, restoring demand for delivery devices. Regional Demand Reflects Veterinary Access and Product Availability North America held the largest estimated regional share of 43.0%, generating approximately USD 0.83 billion in 2025. The regional market is projected to reach around USD 1.32 billion by 2032, growing at a CAGR of 6.8%. North America has a large owned-pet population, established companion-animal healthcare infrastructure, strong online and clinic-based retail channels, and access to veterinary meters, insulin pens, syringes, human CGMs, and FDA-approved oral feline diabetes medicines. The United States is also an important launch market for connected monitoring products. Europe accounted for an estimated 29.0% market share and approximately USD 0.56 billion in 2025. The region is projected to reach around USD 0.91 billion by 2032, expanding at a CAGR of 7.1%. Europe combines a large companion-animal population with established veterinary-device brands and broad availability of Caninsulin/VetPen and WellionVet products. The supplied evidence identifies approximately 104 million dogs and 127 million cats in Europe, although only a small proportion are diagnosed with diabetes or use home-monitoring devices. Asia-Pacific represented approximately 20.0% of global revenue, equivalent to USD 0.39 billion in 2025. It is projected to be the fastest-growing regional market, reaching approximately USD 0.74 billion by 2032 at a CAGR of 9.7%. The region includes veterinary-device manufacturing capabilities through companies such as i-SENS, but public country-level data on diagnosed pets, CGM adoption, insulin-pen penetration, and strip consumption remain limited. Demand is concentrated in urban areas with stronger veterinary access, higher household pet spending, and established distributor networks. Latin America, the Middle East, and Africa collectively accounted for the remaining estimated 8.0% share, or approximately USD 0.16 billion, in 2025. These markets are projected to reach around USD 0.27 billion by 2032, growing at a CAGR of approximately 8.0%. Human glucose meters and generic syringes may be more accessible than veterinary-calibrated systems in price-sensitive markets. Veterinary-specific products are more likely to gain adoption through referral hospitals, urban veterinary chains, online channels, and distributors serving higher-spending pet owners. Competitive Landscape and Product Launch Activity Competition spans veterinary-calibrated meters, veterinary-specific CGMs, human CGMs used off-label in animals, insulin-delivery systems, ketone monitoring, recurring consumables, and connected software. No audited public source provides company-level shares, annual veterinary-device shipments, meter installations, or sensor volumes. Companies are therefore better compared by product portfolios, launch activity, channel strength, and ability to retain recurring consumable revenue. Zoetis Zoetis launched the AlphaTrak 3 Blood Glucose Monitoring System in the United States in February 2023. The generation added a mobile application for collecting, storing, and sharing readings between owners and veterinary teams. The portfolio includes the meter, proprietary strips, lancets, control solution, mobile connectivity, and dog-, cat-, and horse-specific calibration settings. Zoetis benefits from veterinary-practice relationships and a broader Vetscan diagnostic portfolio. AlphaTrak combines periodic meter sales with recurring strip and lancet revenue. Its connected workflow and species calibration support a premium position against lower-priced human meters and specialist direct-to-owner products. Covetrus and ALR Technologies Covetrus introduced the GluCurve Pet CGM in January 2023 through a relationship with ALR Technologies. The system was designed for diabetic dogs and cats and combined a sensor with an owner application and veterinary portal. Following manufacturing redevelopment, ALR Technologies reported the commercial launch of an updated GluCurve generation in May 2026. The current system offers up to 14 days of sensor wear, frequent glucose readings, Bluetooth transfer, food and insulin logs, curve comparisons, onboard data storage, and remote veterinary access. Covetrus also markets the species-calibrated Vet GlucoGauge portable meter, giving it a position in both spot testing and continuous monitoring. GluCurve competes with Abbott FreeStyle Libre through pet-specific application support, veterinary software, clinic-controlled distribution, and animal-focused technical assistance. Abbott Abbott does not market FreeStyle Libre as a veterinary product, but its sensors are widely used in dogs and cats. The company launched FreeStyle Libre 3 in the United States in 2022, adding automatic minute-by-minute transmission to compatible smartphones and connection with LibreView and LibreLinkUp. Abbott benefits from large-scale human CGM manufacturing, pharmacy availability, and established digital infrastructure. Veterinary-specific competitors address the limitations of off-label use through animal-focused placement guidance, clinic dashboards, technical support, and species-specific workflows. Abbott secured a CE Mark in May 2026 for Libre Duo, a human system designed to monitor glucose and ketones continuously. It is not a veterinary product, but dual glucose-ketone sensing indicates a technology direction that could become relevant to animal DKA monitoring if veterinary validation is pursued. Merck Animal Health Merck Animal Health competes through VetPen, Vetsulin cartridges, pen needles, and related owner-support tools. The closed delivery system links a reusable device with recurring cartridge and needle purchases. No newer VetPen generation was identified in the reviewed material, but Merck continues to support the platform through starter kits, dosing tools, and education resources. VetPen competes with conventional U-40 syringes on ease of handling and dose selection. Its commercial base remains strongest among insulin-dependent dogs and cats, while oral feline medicines reduce injection-device demand only within a selected newly diagnosed population. PetTest PetTest operates a specialist direct-to-owner and veterinary-practice model. Its portfolio includes the Classic Meter, connected PetLink+ meter, Digital Companion application, OnTarget glucose and ketone system, glucose strips, blood- and urine-ketone strips, lancets, lancing devices, U-40 syringes, and bundled kits. PetLink+ added wireless synchronization and graphical data sharing, while OnTarget extended the company into dual glucose-ketone monitoring. PetTest competes through online availability, consumable affordability, connected home testing, and the ability to capture spending across monitoring and insulin-administration supplies. MED TRUST, i-SENS, and Adapet MED TRUST markets the WellionVet BELUA glucose and ketone meter, the GLUCO CALEA glucose meter, species-specific strips, code chips, and safety lancets. Its dual-parameter portfolio gives it a stronger position in ketone monitoring, particularly in European and distributor-led markets. i-SENS supplies the VetMate meter and compatible strips. Its current product lacks the wireless connectivity of newer connected systems but benefits from the company’s broader diagnostic manufacturing capabilities and distributor reach. Adapet Medical is developing a veterinary CGM ecosystem that combines a wearable sensor, owner application, veterinary portal, and planned activity and feeding-data products. The company reports a 14-day sensor-wear target and use in more than 1,000 pets, although these figures are company-reported rather than independently verified. Market Outlook Market growth will be driven by increased home monitoring, broader short-term CGM use, recurring consumable demand, and greater ketone surveillance in selected feline diabetes pathways. Connected monitoring applications are projected to record the fastest product CAGR of 12.2%, followed by CGM systems at 11.1%, while home-care users are expected to retain the largest end-user share through 2032. Veterinary-calibrated meters and CGMs will remain complementary. CGMs provide multi-day glucose trends, while portable meters support spot checks, home glucose curves, and confirmation of uncertain sensor readings. Oral feline diabetes therapies may reduce injection-device use in eligible patients but will increase the need for glucose and ketone safety monitoring. Manufacturers with recurring-revenue products, including proprietary strips, replacement sensors, pen needles, insulin cartridges, ketone tests, and connected veterinary platforms, are better positioned than meter-only competitors. Robust market estimates will require primary research on diagnosis, treatment persistence, testing frequency, CGM adoption, therapy mix, pricing, and use of human versus veterinary-specific devices. Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 1.94 Billion Revenue Forecast in 2032 USD 3.24 Billion Overall Growth Rate CAGR of 7.5% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million, CAGR (2026 – 2032) Segmentation By Product, By Application, By End User, By Animal Type, By Geography By Product Veterinary Blood Glucose Meters, Continuous Glucose Monitoring Systems, Blood Glucose Test Strips, Blood Ketone Meters and Test Strips, Lancets and Lancing Devices, Insulin Pens, Insulin Pen Needles, Insulin Syringes, Connected Monitoring Applications and Platforms By Application Routine Blood Glucose Monitoring, Continuous Glucose Monitoring, Insulin Administration, Blood and Urine Ketone Monitoring, Diabetic Ketoacidosis Monitoring, Hypoglycemia Detection, Treatment Response and Dose Monitoring, Feline Diabetes Remission Monitoring By End User Pet Owners and Home-Care Users, Veterinary Clinics, Veterinary Hospitals, Specialty and Emergency Veterinary Hospitals, Veterinary Diagnostic Centers By Animal Type Dogs, Cats By Region North America, Europe, Asia-Pacific, Latin America, Middle East and Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Rising diagnosis of diabetes in companion animals, wider adoption of home-based glucose monitoring, growing use of continuous glucose monitoring systems in veterinary care, increasing pet healthcare expenditure, and expansion of connected diabetes-management platforms Customization Option Available upon request Frequently Asked Question About This Report Q1. How big is the pet diabetes care devices market? A1. The global market was valued at USD 1.94 billion in 2025 and is projected to reach USD 3.24 billion by 2032. Q2. What is the CAGR of the pet diabetes care devices market? A2. The market is projected to grow at a CAGR of 7.5% from 2026 to 2032. Q3. What products are covered in the pet diabetes care devices market report? A3. The report covers glucose meters, continuous monitoring systems, test strips, ketone meters, lancets, insulin pens, needles, syringes, and connected platforms. Q4. Which animal types and end users are included in the report? A4. The report covers dogs and cats across pet owners, veterinary clinics, hospitals, specialty facilities, and diagnostic centers. Q5. What factors are driving the pet diabetes care devices market? A5. Growth is supported by rising pet diabetes diagnosis, home monitoring, continuous glucose tracking, and higher veterinary care spending. Sources: The Addressable Animal Population Depends on Active Disease Management Washington State Animal Welfare Assessment Diabetes Mellitus in Dogs Attending UK Primary-Care Practices Frequency, Risk Factors, and Mortality for Diabetes Mellitus in Cats Recurring Consumables, Home Monitoring, and Complementary CGMs AAHA 2026 Feline Glucose Monitoring Guidelines AAHA Continuous Glucose Monitoring in Dogs and Cats Zoetis AlphaTrak 3 Glucose Monitoring System Insulin Delivery and Oral Feline Diabetes Drugs Merck Animal Health VetPen FDA Bexacat and Senvelgo Guidance FDA Bexacat Safety Conditions Competitive Landscape and Product Launch Activity Zoetis Launches AlphaTrak 3 Covetrus Introduces GluCurve Pet CGM Abbott Launches FreeStyle Libre 3 in the United States Table of Contents - Global Pet Diabetes Care Devices Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Product, Application, End User, Animal Type, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Product, Application, End User, Animal Type, and Region Market Share Analysis Leading Players by Market Presence and Strategic Positioning Market Share Analysis by Product, Application, End User, and Animal Type Investment Opportunities in the Pet Diabetes Care Devices Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Veterinary Blood Glucose Meters, Continuous Glucose Monitoring Systems, Blood Glucose Test Strips, Blood Ketone Meters and Test Strips, Lancets and Lancing Devices, Insulin Pens, Insulin Pen Needles, Insulin Syringes, Connected Monitoring Applications and Platforms, Routine Blood Glucose Monitoring, Continuous Glucose Monitoring, Insulin Administration, Blood and Urine Ketone Monitoring, Diabetic Ketoacidosis Monitoring, Hypoglycemia Detection, Treatment Response and Dose Monitoring, and Feline Diabetes Remission Monitoring Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Pet Diabetes Care Devices in Veterinary Glucose Monitoring, Insulin Administration, Ketone Monitoring, Home-Care Management, and Companion Animal Chronic Disease Support Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Veterinary Care Access, Pet Insurance, Home Monitoring Adoption, and Diabetes Management Protocols Role of Routine Blood Glucose Monitoring, Continuous Glucose Monitoring, Insulin Administration, Blood and Urine Ketone Monitoring, Diabetic Ketoacidosis Monitoring, Hypoglycemia Detection, Treatment Response and Dose Monitoring, and Feline Diabetes Remission Monitoring in Market Expansion Connected Monitoring, Veterinary Workflow Integration, Owner Compliance, and Companion Animal Chronic Care Trends in Pet Diabetes Management Global Pet Diabetes Care Devices Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product: Veterinary Blood Glucose Meters Continuous Glucose Monitoring Systems Blood Glucose Test Strips Blood Ketone Meters and Test Strips Lancets and Lancing Devices Insulin Pens Insulin Pen Needles Insulin Syringes Connected Monitoring Applications and Platforms Market Analysis by Application: Routine Blood Glucose Monitoring Continuous Glucose Monitoring Insulin Administration Blood and Urine Ketone Monitoring Diabetic Ketoacidosis Monitoring Hypoglycemia Detection Treatment Response and Dose Monitoring Feline Diabetes Remission Monitoring Market Analysis by End User: Pet Owners and Home-Care Users Veterinary Clinics Veterinary Hospitals Specialty and Emergency Veterinary Hospitals Veterinary Diagnostic Centers Market Analysis by Animal Type: Dogs Cats Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Pet Diabetes Care Devices Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product, Application, End User, and Animal Type Country-Level Breakdown: United States Canada Mexico Europe Pet Diabetes Care Devices Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product, Application, End User, and Animal Type Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Pet Diabetes Care Devices Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product, Application, End User, and Animal Type Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Pet Diabetes Care Devices Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product, Application, End User, and Animal Type Country-Level Breakdown: Brazil Argentina Rest of Latin America Middle East & Africa Pet Diabetes Care Devices Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product, Application, End User, and Animal Type Country-Level Breakdown: GCC Countries South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Zoetis Inc. Merck Animal Health Boehringer Ingelheim Animal Health Elanco Animal Health Incorporated IDEXX Laboratories, Inc. Heska Corporation Covetrus, Inc. Abbott Laboratories Dexcom, Inc. Trividia Health, Inc. Competitive Landscape and Strategic Insights Benchmarking Based on Veterinary Blood Glucose Meters, Continuous Glucose Monitoring Systems, Blood Glucose Test Strips, Blood Ketone Meters and Test Strips, Lancets and Lancing Devices, Insulin Pens, Insulin Pen Needles, Insulin Syringes, Connected Monitoring Applications and Platforms, Veterinary Distribution Strength, Clinical Usability, and Home-Care Adoption Supplier Qualification and Companion Animal Diabetes Care Capability Analysis Routine Blood Glucose Monitoring and Continuous Glucose Monitoring Positioning Insulin Administration, Blood and Urine Ketone Monitoring, Diabetic Ketoacidosis Monitoring, and Hypoglycemia Detection Competitiveness Treatment Response and Dose Monitoring, Feline Diabetes Remission Monitoring, Dogs, Cats, Pet Owners and Home-Care Users, Veterinary Clinics, Veterinary Hospitals, Specialty and Emergency Veterinary Hospitals, and Veterinary Diagnostic Centers Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Product, Application, End User, Animal Type, and Region (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Vendors Veterinary Compliance, Home-Care Adoption, and Procurement Risk Analysis Technology Adoption Trends Across Veterinary Blood Glucose Meters, Continuous Glucose Monitoring Systems, Blood Glucose Test Strips, Blood Ketone Meters and Test Strips, Lancets and Lancing Devices, Insulin Pens, Insulin Pen Needles, Insulin Syringes, and Connected Monitoring Applications and Platforms List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Presence Growth Strategies Adopted by Key Players Market Share by Product, Application, End User, and Animal Type (2025 vs. 2032) Global Pet Diabetes Care Devices Ecosystem and Value Chain Analysis